PTJ
ATRA icon

Paul Tudor Jones’s Atara Biotherapeutics ATRA Stock Holding History

Paul Tudor Jones’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,331
Closed -$601K – 2391
2022
Q4 		$601K Sell
7,331
-1,494
-17% -$156K 0.01% 1461
2022
Q3 		$834K Buy
8,825
+5,304
+151% +$596K 0.02% 1044
2022
Q2 		$686K Buy
3,521
+1,599
+83% +$261K 0.02% 1097
2022
Q1 		$446K Buy
+1,922
New +$612K 0.01% 1332
2021
Q1 		– Sell
-564
Closed -$277K – 1551
2020
Q4 		$277K Sell
564
-149
-21% -$68.8K 0.01% 1142
2020
Q3 		$231K Buy
+713
New +$243K 0.01% 1092
2020
Q2 		– Sell
-3,039
Closed -$646K – 1165
2020
Q1 		$646K Buy
3,039
+1,269
+72% +$403K 0.06% 388
2019
Q4 		$729K Buy
+1,770
New +$610K 0.03% 603
2016
Q1 		– Sell
-764
Closed -$504K – 1728
2015
Q4 		$504K Buy
+764
New +$578K 0.01% 869

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Paul Tudor Jones's ATRA Position: Q1 2023 in Review

Paul Tudor Jones sold out of Atara Biotherapeutics (ATRA) in Q1 2023, closing a stake of 7,331 shares — an estimated $601K sold.

Paul Tudor Jones first reported a position in ATRA in Q4 2015 and held it in 9 quarters. The position peaked at $834K in Q3 2022. 125 funds tracked by Wall St. Rank hold ATRA as of Q1 2023.

  • Paul Tudor Jones reported no remaining Atara Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 7,331 Atara Biotherapeutics shares in Q1 2023, an estimated $601K.
  • Paul Tudor Jones first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 9 quarters.
  • Paul Tudor Jones's Atara Biotherapeutics position peaked at $834K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2023.

Based on Tudor Investment Corp's 13F filing for Q1 2023, filed 15 May 2023.